GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States…
Not yet scored
50.22
Screen close, 2026-09-18 · not a live quote Last reviewed 4 days ago
Screened 2026-09-18 · the tape above runs as of 13:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 50.22 against the desk's fair-value range, base estimate 52.51, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical screen not yet scored
Price50.22
Fair value52.51
Ethical score50.0/100
RatingFAIR VALUE
Our investment reviews on this name
2026-07-18Read Distribution51.52-2.5% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
GSK PLC (GlaxoSmithKline) holds its Markdown at $50.22. The statistical read favours the sellers, held for 76 days.
As held on the ledger · 2026-09-18
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 76 days
Price at the screen
$50.22
Valuation
12.88 trailing · 9.60 forward price to earnings
Values screen
Not scored· score 50.0
Beta
0.30
The Workings
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads FAIR VALUE: it trades at roughly a 5% discount to our $52.51 fair value, moderate competitive moat, 1.50% revenue growth.
Fair value range in , drawn from the 2026-09-18 screen. The gold marker is the market price at the same screen. A 4.6% margin of safety to the base estimate.
Third-party analyst targets: 8 covering, consensus Hold. The average target sits +15% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-18 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it is worth knowing
A quality business: a moderate moat and 18% profit margins. It trades close to our $52.51 fair value, so the easy discount is gone; you would be paying up for the quality.
The risks · The things to watch: its business and earnings are exposed to United Kingdom and to currency swings; as a drug manufacturers - general name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
GSK trades on NYSE (ADR) (the company is based in United Kingdom). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-29Distribution$51.52+0.0%Entry 12
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (8 analysts) rates it hold, with a mean price target of $59.
2026-07-28Distribution$51.52+0.0%Entry 11
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical pass with moderate score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (8 analysts) rates it hold, with a mean price target of $58. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-27Distribution$51.52+0.0%Entry 10
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical pass with moderate score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (8 analysts) rates it hold, with a mean price target of $58. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-26Distribution$51.52+0.0%Entry 9
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical pass with moderate score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (8 analysts) rates it hold, with a mean price target of $58. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-25Distribution$51.52+0.0%Entry 8
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical pass with moderate score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (8 analysts) rates it hold, with a mean price target of $58. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-24Distribution$51.52+0.0%Entry 7
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical pass with moderate score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (8 analysts) rates it hold, with a mean price target of $58. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-23Distribution$51.52+0.0%Entry 6
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical pass with moderate score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (8 analysts) rates it hold, with a mean price target of $58. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-22Distribution$51.52+0.0%Entry 5
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical pass with moderate score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (8 analysts) rates it hold, with a mean price target of $58. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-21Distribution$51.52+0.0%Entry 4
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical pass with moderate score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (8 analysts) rates it hold, with a mean price target of $58. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-18Distribution$51.52+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical pass with moderate score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (8 analysts) rates it hold, with a mean price target of $58.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.